Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359241284911 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 04.10.2024. Verfasst von Al Jarroudi Ouissam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pancreatic cancer (PC) is an aggressive disease that is challenging to treat and is associated with a high mortality rate. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), and the existing treatment options are insufficient for PDAC patients. Due to the complexity and heterogeneity of PDAC, personalized medicine is necessary for effectively treating this illness. To achieve this, it is essential to understand the mechanism of PDAC carcinogenesis. Targeted therapies are a promising strategy to improve patient outcomes. Aberrant activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays a crucial role in PC pathogenesis, from initiation to progression. This review provides a comprehensive overview of the current state of knowledge regarding the PI3K pathway in PDAC, summarizes clinical data on PI3K pathway inhibition in PDAC, and explores potential effective combinations that are a promising direction requiring further investigation in PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco.
- Faculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco.
ORCID-Profile: Al Jarroudi Ouissam
Zitieren
APA
Ouissam, A. J., Hind, C., Sami Aziz, B., & Said, A. (2024). Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241284911
Vancouver
Ouissam AJ, Hind C, Sami Aziz B, Said A. Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241284911
BibTeX
@article{Ouissam2024,
author = {Ouissam, Al Jarroudi and Hind, Chibani and Sami Aziz, Brahmi and Said, Afqir},
title = {Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359241284911}
}
EUVIMED